Lenvatinib‐associated hemoperitoneum in a patient with primary angiosarcoma of the breast

Key Clinical Message We highlight the risk of lenvatinib drug toxicity when high‐risk anatomic regions are affected by angiosarcoma.

Saved in:
Bibliographic Details
Published in:Clinical case reports 2024-04, Vol.12 (4), p.e8701-n/a
Main Authors: Orabueze, Ijeoma, Akpan, Inemesit, Denley, Ryan
Format: Article
Language:English
Subjects:
Abdomen
Angiogenesis
angiosarcoma
Biopsy
Blood pressure
Breastfeeding & lactation
Cancer therapies
Cardiovascular Disorders
Case Report
Case reports
Clinical trials
Conflicts of interest
Consent
Drug dosages
Editing
Embolization
Gastroenterology/Hepatology
Growth factors
Heart rate
Hematology
hemoperitoneum
Hemorrhage
Hypertension
lenvatinib
Liver cancer
Metastasis
Oncology
Respiratory Medicine
Sarcoma
Ultrasonic imaging
Vascular Surgery
Writing
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Key Clinical Message We highlight the risk of lenvatinib drug toxicity when high‐risk anatomic regions are affected by angiosarcoma.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.8701